Glaxo bribery claims stretch to Syria

GlaxoSmithKline (NYSE:GSK) is now facing corruption claims in Syria, where it's has been accused of bribery to secure business.

The drugmaker is investigating the claims which date back to 2010 after a whistleblower's email was sent to the company.

Syria is now the sixth country to be investigated by Glaxo for smaller-scale bribery claims compared to the $480M Chinese allegations which have plagued the company since last July.

GSK -0.2% AH

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs